One Body, Many Genomes: The Science of Somatic Mosaicism and Its Clinical Consequences
Textbook genetics begins with a reassuring simplicity: a single fertilized egg, a single genome, replicated faithfully into every cell of the body that develops from it. This model is elegant and pedagogically useful. It is also, as modern sequencing technology has made increasingly clear, an approximation. The human body is not a genetically uniform entity. It is, in a meaningful biological sense, a mosaic—a collection of cell populations that may differ from one another at the level of DNA sequence in ways that range from inconsequential to profoundly clinically significant.
The phenomenon responsible for this complexity is called somatic mosaicism. Unlike germline mutations, which are present in the egg or sperm and therefore inherited by every cell in the resulting organism, somatic mutations arise after fertilization, during the cell divisions that build and maintain the body throughout life. Because these mutations occur in a subset of cells rather than all cells, they are not transmitted to offspring—but their effects on the individual who carries them can be substantial.
How Mosaicism Arises
Every time a cell divides, its approximately six billion base pairs of DNA must be copied with high fidelity. The cellular machinery that performs this task is remarkably accurate, but not perfect. Replication errors occur at a low but nonzero rate, and additional mutations arise from exposure to reactive oxygen species generated by normal metabolism, ultraviolet radiation, environmental mutagens, and other sources of DNA damage. Most of these mutations are either repaired or inconsequential. A small fraction, however, persist and are passed to daughter cells, founding a clone of cells that carries a genetic variant absent from the rest of the body.
The timing of a somatic mutation determines the scope of its distribution. A mutation arising during the first few cell divisions of embryonic development may be present in a large fraction of the body's cells, distributed across multiple tissue types. A mutation arising in a single adult stem cell will be confined to the lineage that stem cell produces. This creates a spectrum of mosaicism ranging from variants present in nearly half of all cells—sometimes detectable by standard clinical sequencing—to variants present in a fraction of a percent of cells in a single tissue, detectable only by the most sensitive sequencing approaches.
Clonal Hematopoiesis: Mosaicism in the Blood
Among the best-characterized forms of somatic mosaicism in adults is clonal hematopoiesis—the expansion of blood cell clones carrying somatic mutations in genes associated with leukemia. Large-scale genomic studies of blood samples from tens of thousands of Americans have revealed that clonal hematopoiesis is present in a substantial minority of individuals over age 60, and becomes increasingly prevalent with advancing age. In most cases, these clones do not progress to frank malignancy; however, their presence is associated with elevated risks of cardiovascular disease and all-cause mortality through mechanisms that appear to involve inflammatory signaling.
The discovery of clonal hematopoiesis has reshaped understanding of the relationship between aging, somatic mutation accumulation, and systemic disease risk. It has also created a new category of incidental finding in clinical genomics: when a blood-based genetic test identifies a somatic variant in a cancer-associated gene, clinicians must now consider whether the finding reflects a germline mutation, a tumor-derived mutation in a patient with known cancer, or clonal hematopoiesis in an otherwise healthy individual.
Mosaicism and Rare Disease Diagnosis
For patients with rare genetic diseases, mosaicism introduces diagnostic complexity that can delay or complicate accurate diagnosis. Classic Mendelian conditions—caused by mutations in single genes—are typically diagnosed by identifying the causative variant in a blood sample. But if the causative mutation arose as a somatic event after fertilization, it may be present at a level too low to detect in blood, even if it is abundant in the affected tissue.
Clinicians and researchers have encountered cases in which children with features of a genetic syndrome test negative on standard blood-based sequencing, only to have the causative variant identified when a skin biopsy, buccal swab, or affected tissue sample is analyzed using deep sequencing methods capable of detecting low-frequency variants. Conditions associated with somatic mosaicism include several neurodevelopmental disorders, vascular malformation syndromes, and segmental overgrowth conditions, many of which involve mutations in genes of the PI3K-AKT-mTOR signaling pathway.
Parental mosaicism presents an additional dimension. A parent who carries a somatic mutation in a small fraction of their germline cells may appear genetically unaffected themselves but transmit the mutation to children, in whom it is present in every cell. This pattern can produce what appears to be a de novo mutation in a child—a mutation with no apparent parental origin—when in fact it was inherited from a mosaic parent. Recognizing this possibility has implications for recurrence risk counseling.
Implications for Cancer Risk and Surveillance
Somatic mosaicism is, in one sense, simply the cellular substrate from which cancer emerges. Cancer is fundamentally a disease of somatic mutation—the progressive accumulation of genetic alterations in a cell lineage that confers growth advantage and eventually produces malignant behavior. From this perspective, every cancer is an extreme manifestation of mosaicism.
But the relationship between mosaicism and cancer risk extends beyond this conceptual framing. Individuals who carry mosaic pathogenic variants in established cancer predisposition genes—such as TP53, APC, or BRCA1—may face elevated cancer risk compared to the general population, though typically lower risk than individuals who carry the same variant in every cell. Determining appropriate surveillance strategies for mosaic carriers is an area of active clinical research and ongoing guideline development.
Discordance Between Tissue Types and Testing Implications
The tissue-specificity of somatic mosaicism has direct practical implications for genetic testing. Blood is the most commonly used sample type for clinical genetic testing in the United States, and it provides a reasonable proxy for constitutional genotype in most circumstances. However, it is not a universal proxy. A somatic mutation present in skin but not blood, or in brain but not blood, will not be identified by a blood-based test.
This discordance also affects the interpretation of ancestry and consumer genetic testing. Saliva-based tests, which capture cells from the buccal epithelium as well as white blood cells, sample a mixture of tissue types. In individuals with significant mosaicism, results from saliva may differ subtly from results that would be obtained from blood or from other tissues. While such discordance is rarely clinically significant in the context of ancestry testing, it underscores the principle that a genetic test result always reflects the sample analyzed, not necessarily the genome of the entire organism.
A More Complex Picture of Genetic Identity
The growing recognition of somatic mosaicism does not undermine the utility of genetic testing; rather, it refines the interpretive framework within which results must be understood. Every individual harbors a unique history of somatic mutation, accumulated across a lifetime of cell division and environmental exposure. This history is written in the genomes of individual cell populations, and reading it requires both technological sensitivity and interpretive sophistication.
For the field of genomic medicine, mosaicism represents both a diagnostic challenge and a scientific opportunity. Understanding which somatic variants matter, in which tissues, and at which frequencies will require continued investment in high-sensitivity sequencing methods, large-scale tissue-specific genomic studies, and the clinical expertise to translate these findings into actionable guidance for patients and providers.
